Indication
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
Loading your page…
Loading your page…
Breast Neoplasms
Marketing Authorisation Holder: Orion Corporation
EMA Authorisation: 14/02/1996
INN: toremifene
AI Drug & Interaction Analysis
Free account required
Ask Osler about Fareston: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.